ADCYAP1 and plasma cell myeloma: For instance, PACAP has protected the kidney from ischemia-induced kidney injuries [14], myeloma injuries [21], cisplatin-induced renal failure [22], cyclosporine A-induced nephrotoxicity [23], and DN [18].